Works matching IS 21989788 AND DT 2025 AND VI 12 AND IP 1


Results: 17
    1
    2
    3
    4

    Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA: TRD Disability Burden for Patients Initiated on Esketamine and Conventional Therapies: M. K. Jha et al

    Published in:
    Drugs - Real World Outcomes, 2025, v. 12, n. 1, p. 35, doi. 10.1007/s40801-024-00478-3
    By:
    • Jha, Manish K.;
    • Zhdanava, Maryia;
    • Shah, Aditi;
    • Voegel, Arthur;
    • Tardif-Samson, Anabelle;
    • Pilon, Dominic;
    • Joshi, Kruti
    Publication type:
    Article
    5

    Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study: Real-World Data of the Use of the Adalimumab Biosimilar SB5: B. Fautrel et al

    Published in:
    2025
    By:
    • Fautrel, Bruno;
    • Bouhnik, Yoram;
    • Salliot, Carine;
    • Carbonnel, Franck;
    • Fumery, Mathurin;
    • Bernardeau, Christophe;
    • Maugars, Yves;
    • Flamant, Mathurin;
    • Coury, Fabienne;
    • Braithwaite, Ben;
    • Hateb, Salima;
    • Addison, Janet
    Publication type:
    Correction Notice
    7
    8

    Association Between Inappropriate Prescribing According to the 2023 Beers Criteria and Different Health Outcomes: A 1-Year Longitudinal Study in Community-Dwelling Older Adults: Longitudinal Association Between 2023 Beers Criteria and Health Outcomes: R. M. da Silva et al

    Published in:
    Drugs - Real World Outcomes, 2025, v. 12, n. 1, p. 93, doi. 10.1007/s40801-024-00474-7
    By:
    • da Silva, Rosiane Mendes;
    • Lucchetti, Alessandra Lamas Granero;
    • Ferreira, Maria Eduarda Corradi;
    • Silva, Leonardo Oliveira;
    • da Silva Ezequiel, Oscarina;
    • Martins, Eduardo Luiz Mendonça;
    • Lucchetti, Giancarlo
    Publication type:
    Article
    9
    10
    11
    12
    14

    Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan University: Adverse Reactions: Naxitamab China Expanded Access: X. Qian et al.

    Published in:
    Drugs - Real World Outcomes, 2025, v. 12, n. 1, p. 115, doi. 10.1007/s40801-024-00468-5
    By:
    • Qian, Xiaowen;
    • Zhang, Dufei;
    • Li, Kai;
    • Chen, Weiming;
    • Zhuang, Peijun;
    • Wang, Hongsheng;
    • Lei, Zhixian;
    • Li, Yan;
    • Eldridge, James;
    • Dong, Kuiran;
    • Zhai, Xiaowen
    Publication type:
    Article
    15
    16
    17